Lack of clinically significant pharmacokinetic interactions between zonisamide and lamotrigine at steady state in patients with epilepsy

Therapeutic Drug Monitoring

Volumn 27, Issue 2, 2005, Pages 193-198

  Levy, Rene H ^a   Ragueneau Majlessi, Isabelle ^a   Brodie, Martin J ^b   Smith, David F ^c   Shah, Jaymin ^d,e   Pan, Wei Jian ^e  

^a UNIVERSITY OF WASHINGTON   (United States)

^b WESTERN INFIRMARY   (United Kingdom)

^c WALTON CENTRE FOR NEUROLOGY AND NEUROSURGERY   (United Kingdom)

^d GILEAD SCIENCES   (United States)

^e ELAN PHARMACEUTICALS   (United States)

Author keywords

Drug interactions; Epilepsy; Lamotrigine; Pharmacokinetics; Zonisamide

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; ANTICONVULSIVE AGENT; LAMOTRIGINE; ZONISAMIDE;

ACETYLATION; ADULT; ANOREXIA; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONCENTRATION LOSS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIZZINESS; DRUG ACETYLATION; DRUG BLOOD LEVEL; DRUG DISPOSITION; DRUG GLUCURONIDATION; DRUG SAFETY; DRUG URINE LEVEL; DYSPEPSIA; EPILEPSY; FATIGUE; FEMALE; HEADACHE; HUMAN; LIVER DYSFUNCTION; MALE; MAXIMUM TOLERATED DOSE; MULTICENTER STUDY; NAUSEA; PRIORITY JOURNAL; SIDE EFFECT; STEADY STATE;

ADULT; AREA UNDER CURVE; DRUG ADMINISTRATION SCHEDULE; DRUG MONITORING; DRUG THERAPY, COMBINATION; EPILEPSY; FEMALE; HUMANS; ISOXAZOLES; LIVER; MALE; TIME FACTORS; TRIAZINES;

EID: 16244368493     PISSN: 01634356     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.ftd.0000153403.99478.1f     Document Type: Article

References (24)

1. Hachad H, Ragueneau-Majlessi I, Levy RH. New antiepileptic drugs: review on drug interactions. Ther Drug Monit. 2002;24:91-103.
2. Stephen LJ, Brodie MJ. Lamotrigine: Clinical efficacy and use in epilepsy. In: Levy RH, Mattson RH, Meldrum BS, Perucca E, eds. Antiepileptic Drugs. Philadelphia: Lippincott Williams & Wilkins, 2002. pp 389-402.
3. Dickins M, Chen C. Lamotrigine: Chemistry, biotransformation, and pharmacokinetics. In: Levy RH, Mattson RH, Meldrum BS, Perucca E, eds. Antiepileptic Drugs. Philadelphia: Lippincott Williams & Wilkins, 2002, pp 370-379.
4. Green MD, Tephly TR. Glucuronidation of amines and hydroxylated xenobiotics and endobiotics catalyzed by expressed human ugt1.4 protein. Drug Metab Dispos. 1996;24:356-363.
5. Yuen AW, Land G, Weatherley BC, et al. Sodium valproate acutely inhibits lamotrigine metabolism. Br J Clin Pharmacol. 1992;33:511-513.
6. Anderson GD, Yau MK, Gidal BE, et al. Bidirectional interaction of valproate and lamotrigine in healthy subjects. Clin Pharmacol Ther. 1996;60:145-156.
7. Kanner AM, Frey M. Adding valproate to lamotrigine: a study of their pharmacokinetic interaction. Neurology. 2000;55:588-591.
8. May TW, Rambeck B, Jurgens U. Serum concentrations of lamotrigine in epileptic patients: the influence of dose and comedication. Ther Drug Monit. 1996;18:523-531.
9. Anderson GD, Gidal BE, Messenheimer JA, et al. Time course of lamotrigine de-induction: impact of step-wise withdrawal of carbamazepine or phenytoin. Epilepsy Res. 2002;49:211-217.
10. Faught E, Ayala R, Montouris GG, et al. Randomized controlled trial of zonisamide for the treatment of refractory partial-onset seizures. Neurology. 2001;57:1774-1779.
11. Seino M, Fujitani B. Zonisamide: clinical efficacy and use in epilepsy. In: Levy RH, Mattson RH, Meldrum BS, Perucca E, eds. Antiepileptic Drugs. Philadelphia: Lippincott Williams & Wilkins, 2002, pp 885-891.
12. Sobieszek G, Borowicz KK, Kimber-Trojnar Z, et al. Zonisamide: A new antiepileptic drug. Pol J Pharmacol. 2003;55:683-689.
13. Perucca E, Bialer M. The clinical pharmacokinetics of the newer antiepileptic drugs. Focus on topiramate, zonisamide and tiagabine. Clin Pharmacokinet. 1996;31:29-46.
14. Mather G, Carlson S, Trager W, et al. Prediction of zonisamide interactions based on metabolic isozymes. Epilepsia. 1997;38(Suppl 8): 108.
15. Ragueneau-Majlessi I, Levy RH, Bergen D, et al. Carbamazepine pharmacokinetics are not affected by zonisamide: in vitro mechanistic study and in vivo clinical study in epileptic patients. Epilepsy Res. 2004; 62:1-11.
16. Ethell BT, Anderson GD, Burchell B. The effect of valproic acid on drug and steroid glucuronidation by expressed human UDP-glucuronosyltransferases. Biochem Pharmacol. 2003;65:1441-1449.
17. Ragueneau-Majlessi I, Levy RH, Brodie M, et al. Lack of pharmacokinetic interaction between steady-state zonisamide and valproic acid in patients with epilepsy. Clin Pharmacokinet.(in press).
18. Liston HL, Markowitz JS, DeVane CL. Drug glucuronidation in clinical psychopharmacology J Clin Psychopharmacol. 2001;21:500-515.
19. Yamashita S, Furuno K, Moriyama M, et al. Effects of various anti-epileptic drugs on plasma levels of lamotrigine, a novel antiepileptic, in rats. Pharmacology. 1997;54:319-327.
20. Mimaki T. Clinical pharmacology and therapeutic drug monitoring of zonisamide. Ther Drug Monit. 1998;20:593-597.
21. Nakasa H, Komiya M, Ohmori S, et al. Characterization of human liver microsomal cytochrome p450 involved in the reductive metabolism of zonisamide. Mol Pharmacol. 1993;44:216-221.
22. Nakasa H, Nakamura H, Ono S, et al. Prediction of drug-drug interactions of zonisamide metabolism in humans from in vitro data. Eur J Clin Pharmacol. 1998;54:177-183.
23. Rambeck B, Wolf P. Lamotrigine clinical pharmacokinetics. Clin Pharmacokinet. 1993;25:433-443.
24. Hussein Z, Posner J. Population pharmacokinetics of lamotrigine monotherapy in patients with epilepsy: retrospective analysis of routine monitoring data. Br J Clin Pharmacol. 1997;43:457-465.